UCB's Global Corporate Website
Welcome to UCB in the United States

Feb

25

Recognizing Rare Disease Day Every Day – The Importance of Addressing Unmet Patient Needs

At UCB, we work 365-days-a-year to find new ways to deliver solutions, peace of mind, and opportunities to people living with severe diseases because everyone deserves to live the best life they can.

Feb

22

Partnering for Greater Impact with Microsoft in R&D

At UCB, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs. 

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

19

UCB to acquire Zogenix

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Dec

03

Unleashing the Power of Digital Solutions in Epilepsy Care

UCB’s Head of Digital Business Transformation, Colin Lake speaks to the current landscape in digital business transformation and neurology.

Dec

03

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care